The role of presepsin in the diagnosis of chronic obstructive pulmonary disease acute exacerbation with pneumonia

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Celli BR, Vestbo J. The EXACT-pro: measuring exacerbations of COPD. Am. J. Respir. Crit. Care Med. 183(3), 287–288 (2011).
  MedlineGoogle Scholar
• 2. Vogelmeier CF, Criner GJ, Martinez FJ et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am. J. Respir. Crit. Care Med. 195(5), 557–582 (2017).
  Medline CASGoogle Scholar
• 3. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 370(9589), 786–796 (2007).
  MedlineGoogle Scholar
• 4. Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax 61(3), 250–258 (2006).
  Medline CASGoogle Scholar
• 5. Restrepo MI, Mortensen EM, Pugh JA et al. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur. Respir. J. 28, 346–351 (2006).
  Medline CASGoogle Scholar
• 6. Lacoma A, Prat C, Andreo F et al. Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 6, 157–169 (2011).
  MedlineGoogle Scholar
• 7. Huerta A, Crisafulli E, Menendez R et al. Pneumonic and nonpneumonic exacerbations of COPD: inflammatory response and clinical characteristics. Chest 144(4), 1134–1142 (2013). • Compared inflammatory markers between pneumonia and nonpneumonic cause in chronic obstructive pulmonary disease (COPD) acute exacerbations.
  Medline CASGoogle Scholar
• 8. Titova E, Christensen A, Henriksen AH, Steinshamn S, Asberg A. Comparison of procalcitonin, C-reactive protein, white blood cell count and clinical status in diagnosing pneumonia in patients hospitalized with acute exacerbations of COPD: a prospective observational study. Chron. Respir. Dis. 16, 1479972318769762 (2019). •• Similar to our study, the role of procalcitonin in the diagnosis of pneumonia associated with acute exacerbation of COPD was investigated.
  MedlineGoogle Scholar
• 9. Taghizadieh A, Soleimanpour H, Rahmani F, Nia KS, Khodaverdizadeh H. Comparison of serum levels of procalcitonin and C-reactive protein in patients with community acquired pneumonia and COPD exacerbation. Iran Red. Crescent. Med. J. 18(12), e25811 (2016).
  Google Scholar
• 10. Kawamatawong T, Apiwattanaporn A, Siricharoonwong W. Serum inflammatory biomarkers and clinical outcomes of COPD exacerbation caused by different pathogens. Int. J. Chron. Obstruct. Pulmon. Dis. 12, 1625–1630 (2017).
  Medline CASGoogle Scholar
• 11. Su YJ. The value of C-reactive protein in emergency medicine. J. Acute Dis. 3(1), 1–5 (2014).
  Google Scholar
• 12. Shirakawa K, Naitou K, Hirose J, Takahashi T, Furusako S. Presepsin (sCD14-ST): development and evaluation of one-step ELISA with a new standard that is similar to the form of presepsin in septic patients. Clin. Chem. Lab. Med. 49(5), 937–939 (2011).
  Medline CASGoogle Scholar
• 13. Mussap M, Puxeddu E, Burrai P et al. Soluble CD14 subtype (sCD14-ST) presepsin in critically ill preterm newborns: preliminary reference ranges. J. Matern. Fetal Neonatal. Med. 25(Suppl. 5), 51–53 (2012).
  Medline CASGoogle Scholar
• 14. Liu B, Chen YX, Yin Q, Zhao YZ, Li CS. Diagnostic value and prognostic evaluation of presepsin for sepsis in an emergency department. Crit. Care. 17(5), R244 (2013). • A study on the importance of presepsin in infection and sepsis in the emergency department.
  MedlineGoogle Scholar
• 15. Romualdo LG, Torrella PE, Gonzales MV et al. Diagnostic accuracy of presepsin (soluble CD14 subtype) for prediction of bacteremia in patients with systemic inflammatory response syndrome in the emergency department. Clin. Biochem. 47(7–8), 505–508 (2014).
  Medline CASGoogle Scholar
• 16. Klouche K, Cristol JP, Devin J et al. Diagnostic and prognostic value of soluble CD14 subtype (presepsin) for sepsis and community-acquired pneumonia in ICU patients. Ann. Intensive Care. 6(1), 59 (2016). •• Reports that presepsin can be used to diagnose severe community-acquired pneumonia, sepsis and severe sepsis in patients admitted to the intensive care unit due to acute respiratory failure.
  MedlineGoogle Scholar
• 17. Taylan M, Demir M, Selimoglu Sen H et al. Alterations of the neutrophil-lymphocyte ratio during the period of stable and acute exacerbation of chronic obstructive pulmonary disease patients. Clin. Respir. J. 11(3), 311–317 (2017).
  Medline CASGoogle Scholar
• 18. In E, Kuluöztürk M, Öner Ö, Deveci F. The importance of neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease. Turk. Thorac. J. 17(2), 41–46 (2016).
  MedlineGoogle Scholar
• 19. van Beurden WJ, Smeen FW, Harff GA, Dekhuijzen PN. Markers of inflammation and oxidative stress during lower respiratory tract infections in COPD patients. Monaldi. Arch. Chest Dis. 59(4), 273–280 (2003).
  Medline CASGoogle Scholar
• 20. Hopstaken RM, Muris JW, Knottnerus JA, Kester AD, Rinkens PE, Dinant GJ. Contributions of symptoms, signs, erythrocyte sedimentation rate, and C-reactive protein to a diagnosis of pneumonia in acute lower respiratory tract infection. Br. J. Gen. Pract. 53(490), 358–364 (2003).
  Medline CASGoogle Scholar
• 21. Anas A, van der Poll T, de Vos AF. Role of CD14 in lung inflammation and infection. Crit. Care. 14(2), 209 (2010).
  MedlineGoogle Scholar
• 22. Liu B, Yin Q, Chen YX, Zhao YZ, Li CS. Role of presepsin (sCD14-ST) and the CURB65 scoring system in predicting severity and outcome of community-acquired pneumonia in an emergency department. Respir. Med. 108(8), 1204–1213 (2014). • Reports that presepsin can be used to determine the severity of community-acquired pneumonia in the emergency department.
  MedlineGoogle Scholar
• 23. Qi ZJ, Yu H, Zhang J, Li CS. Presepsin as a novel diagnostic biomarker for differentiating active tuberculosis from bacterial community acquired pneumonia. Clin. Chim. Acta 478, 152–156 (2018).
  Medline CASGoogle Scholar
• 24. Chenevier-Gobeaux C, Trabattoni E, Roelens M, Borderie D, Claessens YE. Presepsin (sCD14-ST) in emergency department: the need for adapted threshold values. Clin. Chim. Acta 1(427), 34–36 (2014).
  Google Scholar
• 25. Tong X, Cao Y, Yu M, Han C. Presepsin as a diagnostic marker for sepsis: evidence from a bivariate meta-analysis. Ther. Clin. Risk Manag. 2(11), 1027–1033 (2015).
  Google Scholar
• 26. Yaegashi Y, Shirakawa K, Sato N et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J. Infect. Chemother. 11(5), 234–238 (2005).
  Medline CASGoogle Scholar
• 27. Behnes M, Bertsch T, Lepiorz D et al. Diagnostic and prognostic utility of soluble CD14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment. Crit. Care. 218(5), 507 (2014).
  Google Scholar
• 28. Endo S, Suzuki Y, Takahashi G et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J. Infect. Chemother. 18(6), 891–897 (2012).
  Medline CASGoogle Scholar